Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) has shared an announcement.
Shanghai Bio-Heart Biological Technology Co., Ltd. has announced the termination of its 2022 H Share Incentive Scheme, along with the repurchase and cancellation of H shares, and a reduction in registered share capital. This decision, aimed at reducing administrative costs, will not impact the company’s public float or operational performance. The company plans to handle the repurchase and cancellation process in compliance with relevant regulations, pending shareholder approval at the upcoming annual general meeting.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-Heart Biological Technology Co., Ltd. is a joint stock company based in China, operating in the biotechnology sector. The company focuses on developing and providing biological technology solutions, though specific products or services are not detailed in the announcement.
Average Trading Volume: 358,571
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.06B
For detailed information about 2185 stock, go to TipRanks’ Stock Analysis page.